Johnson & Johnson operates in 2 segments: Innovative Medicine and MedTech.
Paying user area
Try for free
Johnson & Johnson pages available for free this week:
- Statement of Comprehensive Income
- Cash Flow Statement
- Analysis of Liquidity Ratios
- Analysis of Solvency Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Net Profit Margin since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Johnson & Johnson for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Segment Profit Margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 29, 2019 | |
---|---|---|---|---|---|
Innovative Medicine | |||||
MedTech |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29).
Segment profitability ratio | Reportable segment | The company |
---|---|---|
Segment profit margin | Innovative Medicine | Innovative Medicine segment profit margin ratio deteriorated from 2021 to 2022 but then improved from 2022 to 2023 exceeding 2021 level. |
MedTech | MedTech segment profit margin ratio improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |
Segment Profit Margin: Innovative Medicine
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 29, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Income (loss) before tax | |||||
Sales to customers | |||||
Segment Profitability Ratio | |||||
Segment profit margin1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29).
1 2023 Calculation
Segment profit margin = 100 × Income (loss) before tax ÷ Sales to customers
= 100 × ÷ =
Segment profitability ratio | Reportable segment | The company |
---|---|---|
Segment profit margin | Innovative Medicine | Innovative Medicine segment profit margin ratio deteriorated from 2021 to 2022 but then improved from 2022 to 2023 exceeding 2021 level. |
Segment Profit Margin: MedTech
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 29, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Income (loss) before tax | |||||
Sales to customers | |||||
Segment Profitability Ratio | |||||
Segment profit margin1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29).
1 2023 Calculation
Segment profit margin = 100 × Income (loss) before tax ÷ Sales to customers
= 100 × ÷ =
Segment profitability ratio | Reportable segment | The company |
---|---|---|
Segment profit margin | MedTech | MedTech segment profit margin ratio improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |
Segment Return on Assets (Segment ROA)
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 29, 2019 | |
---|---|---|---|---|---|
Innovative Medicine | |||||
MedTech |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29).
Segment profitability ratio | Reportable segment | The company |
---|---|---|
Segment ROA | Innovative Medicine | Innovative Medicine segment ROA improved from 2021 to 2022 and from 2022 to 2023. |
MedTech | MedTech segment ROA deteriorated from 2021 to 2022 and from 2022 to 2023. |
Segment ROA: Innovative Medicine
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 29, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Income (loss) before tax | |||||
Identifiable assets | |||||
Segment Profitability Ratio | |||||
Segment ROA1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29).
1 2023 Calculation
Segment ROA = 100 × Income (loss) before tax ÷ Identifiable assets
= 100 × ÷ =
Segment profitability ratio | Reportable segment | The company |
---|---|---|
Segment ROA | Innovative Medicine | Innovative Medicine segment ROA improved from 2021 to 2022 and from 2022 to 2023. |
Segment ROA: MedTech
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 29, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Income (loss) before tax | |||||
Identifiable assets | |||||
Segment Profitability Ratio | |||||
Segment ROA1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29).
1 2023 Calculation
Segment ROA = 100 × Income (loss) before tax ÷ Identifiable assets
= 100 × ÷ =
Segment profitability ratio | Reportable segment | The company |
---|---|---|
Segment ROA | MedTech | MedTech segment ROA deteriorated from 2021 to 2022 and from 2022 to 2023. |
Segment Asset Turnover
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 29, 2019 | |
---|---|---|---|---|---|
Innovative Medicine | |||||
MedTech |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29).
Segment activity ratio | Reportable segment | The company |
---|---|---|
Segment asset turnover | Innovative Medicine | Innovative Medicine segment asset turnover ratio improved from 2021 to 2022 and from 2022 to 2023. |
MedTech | MedTech segment asset turnover ratio deteriorated from 2021 to 2022 but then slightly improved from 2022 to 2023. |
Segment Asset Turnover: Innovative Medicine
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 29, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Sales to customers | |||||
Identifiable assets | |||||
Segment Activity Ratio | |||||
Segment asset turnover1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29).
1 2023 Calculation
Segment asset turnover = Sales to customers ÷ Identifiable assets
= ÷ =
Segment activity ratio | Reportable segment | The company |
---|---|---|
Segment asset turnover | Innovative Medicine | Innovative Medicine segment asset turnover ratio improved from 2021 to 2022 and from 2022 to 2023. |
Segment Asset Turnover: MedTech
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 29, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Sales to customers | |||||
Identifiable assets | |||||
Segment Activity Ratio | |||||
Segment asset turnover1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29).
1 2023 Calculation
Segment asset turnover = Sales to customers ÷ Identifiable assets
= ÷ =
Segment activity ratio | Reportable segment | The company |
---|---|---|
Segment asset turnover | MedTech | MedTech segment asset turnover ratio deteriorated from 2021 to 2022 but then slightly improved from 2022 to 2023. |
Segment Capital Expenditures to Depreciation
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 29, 2019 | |
---|---|---|---|---|---|
Innovative Medicine | |||||
MedTech |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29).
Segment financial ratio | Reportable segment | The company |
---|---|---|
Segment capital expenditures to depreciation | Innovative Medicine | Innovative Medicine segment capital expenditures to depreciation ratio improved from 2021 to 2022 and from 2022 to 2023. |
MedTech | MedTech segment capital expenditures to depreciation ratio improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |
Segment Capital Expenditures to Depreciation: Innovative Medicine
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 29, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Additions to property, plant & equipment | |||||
Depreciation and amortization | |||||
Segment Financial Ratio | |||||
Segment capital expenditures to depreciation1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29).
1 2023 Calculation
Segment capital expenditures to depreciation = Additions to property, plant & equipment ÷ Depreciation and amortization
= ÷ =
Segment financial ratio | Reportable segment | The company |
---|---|---|
Segment capital expenditures to depreciation | Innovative Medicine | Innovative Medicine segment capital expenditures to depreciation ratio improved from 2021 to 2022 and from 2022 to 2023. |
Segment Capital Expenditures to Depreciation: MedTech
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 29, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Additions to property, plant & equipment | |||||
Depreciation and amortization | |||||
Segment Financial Ratio | |||||
Segment capital expenditures to depreciation1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29).
1 2023 Calculation
Segment capital expenditures to depreciation = Additions to property, plant & equipment ÷ Depreciation and amortization
= ÷ =
Segment financial ratio | Reportable segment | The company |
---|---|---|
Segment capital expenditures to depreciation | MedTech | MedTech segment capital expenditures to depreciation ratio improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |
Sales to customers
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 29, 2019 | |
---|---|---|---|---|---|
Innovative Medicine | |||||
MedTech | |||||
Segments total |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29).
Income (loss) before tax
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 29, 2019 | |
---|---|---|---|---|---|
Innovative Medicine | |||||
MedTech | |||||
Segments total |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29).
Identifiable assets
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 29, 2019 | |
---|---|---|---|---|---|
Innovative Medicine | |||||
MedTech | |||||
Segments total |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29).
Additions to property, plant & equipment
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 29, 2019 | |
---|---|---|---|---|---|
Innovative Medicine | |||||
MedTech | |||||
Segments total |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29).
Depreciation and amortization
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 29, 2019 | |
---|---|---|---|---|---|
Innovative Medicine | |||||
MedTech | |||||
Segments total |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29).